Introduction
Edelfosine is considered the prototype of a promising class of antitumor agents, collectively known as alkyl-lysophospholipid analogues or antitumor ether lipids. These agents present the singular characteristic of not targeting the DNA, but affecting the cell membrane and the apoptotic machinery of the cancer cell [1] . Recent in vitro studies have shown that edelfosine is preferentially uptaken by tumoral cells, sparing normal cells [2] .
However, edelfosine presents some drawbacks when administered intravenously, as dose-dependent hemolysis that hampers its administration at certain doses [3] ; and gastrointestinal irritation when administered orally [4, 5] .
In addition, edelfosine presents bioavailability values below 10 % after a single oral administration of 30 mg/kg; however, this bioavailability increased to 64 % after multiple oral administration of the same dose after six days [2] .
Owing to the drawbacks of this molecule, there has been an attempt to design new drug delivery systems that can modify the absorption rate, selectively transport the drug to the target, modifying the drug distribution profile and extending the drug release time in order to improve drug bioavailability, and decrease its toxicity. Among the different lipid-made colloidal carriers, edelfosine was incorporated into liposomes [6] and lipid nanoparticles (LN) made of biocompatible lipids [7] . The liposomal formulation was able to prevent the hemolytic toxicity of the drug, but the main inconvenience found was its rapid clearance from plasma. Edelfosine-loaded liposomes showed both in vivo and in vitro activity against methylnitrosourea-induced tumors, and it was approximately 4 -8 times less acutely toxic than free edelfosine. Edelfosine-5 loaded LN developed by our group were considered another alternative to deliver the drug to the organism [7] . These carriers are colloidal transporters composed of a biocompatible and biodegradable lipid matrix. They combine advantages of liposomes, polymeric nanoparticles and emulsions, while diminishing possible drawbacks associated with them [8] . Lipids employed to form these lipid cores are biodegradable raw materials that are biocompatible: triglycerides (i.e. tristearin), partial glycerides (i.e. Compritol ® 888 ATO and Precirol ® ATO 5), fatty acids (i.e. stearic acid), steroids (i.e. cholesterol) or waxes (i.e. cetyl palmitate) [9] . The formulation methods are also diverse [9, 10] . However, most techniques employ organic solvents, which may imply regulatory and toxicity issues. Moreover, an improvement of LN over the liposomes is their physical and chemical long-term stability up to 12 -24 months [11] . The freeze-drying process of LN has been shown to increase their physicochemical stability over long periods of time [12] . Besides, LN have attracted rising interest for their ability to overcome certain biological barriers, resulting in increased therapeutic efficacy of the encapsulated drug and increase in tumor accumulation [13] .
Mantle cell lymphoma (MCL) is a B-cell malignancy that comprises about 7
% of all non-Hodgkin's lymphomas (NHLs), which is characterized clinically by extranodal disease in older male patients who present at an advanced stage [14] . Even though most patients initially gain a benefit from systemic treatments, the responses obtained are generally of limited duration. As a result, patients generally relapse with less responsive disease, showing a consistently bad outcome with a median overall survival from diagnosis of 43 months [15, 16] .
Several approaches using more severe combination chemotherapy, namely 6 stem cell transplantation, have shown higher response rates and more lasting remission in selected patients, but the greater part of MCL patients are not candidates for such dose-intensive regimens [17, 18] . MCL has recently become an area of intense clinical research, and it appears that median overall survival may be improving, but MCL is still considered incurable with current treatments [19] . Although several cytotoxic combinations including cisplatin, gemcitabine, carmustine and other alkylating drugs have been employed, their inherent toxicity is considered the main drawback at the time of election [20] .
In a previous study, we determined that edelfosine displays a biexponential pharmacokinetic behavior in mice, presenting no significant differences regardless of the mouse strain employed [2] . The tissue distribution of edelfosine in mice shows that the drug is widely scattered across different organs, although it is preferentially internalized by the tumor both in vitro and in vivo. The present work tries to point out how the biodistribution and pharmacokinetic profile of edelfosine is altered compared to that of the free drug, when it is encapsulated in LN. The efficacy of the chemotherapeutic potential of edelfosine loaded LN via the oral route in experimental murine lymphoma xenograft model was also evaluated.
Materials and Methods

Chemicals
Edelfosine was from APOINTECH (Salamanca, Spain (PAF) and PBS (10 mM phosphate, 0.9 % NaCl) were obtained from SigmaAldrich (Madrid, Spain). Chloroform was purchased from Panreac (Madrid, Spain) and methanol was obtained from Merck (Barcelona, Spain). All other solvents were of analytical grade.
Preparation of LN incorporating edelfosine
LN were prepared by the hot homogenization method followed by high shear homogenization and ultrasonication. electrophoresis [21, 22] . Samples were diluted with distilled water (pH 5.5) and each experiment was performed in triplicate. All data are expressed as a mean value ± standard deviation.
Loading capacity
Edelfosine was quantified by an ultra high-performance liquid chromatography tandem mass spectrometry (UHPLC-MS/MS) method that had been previously validated [23] . The drug was extracted from a sample of 10 mg of lyophilized nanoparticles, to which 1 ml of chloroform was added in order to dissolve them. 10 µL of the internal standard PAF (0.2 mg/mL) were then spiked to the samples. 3 mL of methanol were added to the mixture, and after vortex mixing for 1 min at room temperature and centrifuging at 20,000 × g for 10 min, 2 µL aliquots of the supernatant were injected into the chromatographic system. 
Hemolysis experiments
Erythrocytes from fresh human blood were separated from plasma by centrifugation (4,000 x g, 7 min) and washed three times with PBS. 4 mL of the washed erythrocyte suspension were diluted to 100 mL with PBS. 1.5 mL of this suspension were treated with 0. EDTA surface-coated tubes and then centrifuged at 2,000 × g for 10 min (4 ºC) to separate the plasma (100 µL). Then, animals were sacrificed and spleen, liver, lungs, kidneys, heart, stomach and intestine were collected and weighed.
Tissues were homogenised in 1 mL of PBS pH=7.4 using a Mini-bead Beater (BioSpect Products, Inc., Bartelsville, Oklahoma, USA) and centrifuged at 10,000 × g for 10 min. Both plasma and tissue supernatants were collected and stored at -80 ºC until UHPLC-MS/MS analysis was performed.
Pharmacokinetic and biodistribution studies after oral administration
Three BALB/c mice groups (n=8 per group) were treated with a single oral administration of free edelfosine (50 mg/kg) and edelfosine-loaded LN (edelfosine concentration of 50 mg/kg sacrifice by cervical dislocation, tissues were collected, weighed and processed as explained above.
Lymphatic absorption studies
BALB/c mice (n=8 per group) received oral doses of free edelfosine (group 1), Compritol LN (group 2) and Precirol LN (group 3) (edelfosine concentration of 50 mg/kg). 24 hours later, an oily emulsion (milk) was orally administered 1 hour prior to sacrifice, in order to make the lymph ducts and nodes more visible, animals were sacrificed and mesenteric lymph nodes were spotted close to the ascending colon, extracted with the aid of dissection forceps. Then, they were processed like the rest of the organs and analyzed by UHPLC-MS/MS.
Efficacy studies
Cell culture studies
The human mantle-cell lymphoma cell line JVM-2 (DSMZ, Germany) was grown in RPMI-1640 containing 10 % heat-inactivated fetal calf serum (GIBCO/BRL, Carlsbad, CA, USA), 2 mM of L-glutamine, 100 µg/ml streptomycin sulphate (Sigma) and 100 U/ml penicillin (Sigma), at 37 ºC in a humidified atmosphere of air containing 5 % CO 2 .
Animal studies
Eight-week SCID mice were subcutaneously inoculated into the lower dorsum with 1 x 10 7 JVM-2 cells in 100 µL of PBS and 100 µL of Matrigel 
Data analysis
Pharmacokinetic analysis was performed with plasma samples obtained from experiments with all mice. All these plasma concentration data were analyzed by non-compartmental and compartmental analysis using WinNonlin Professional Edition Version 2.1 (Pharsight, Mountain View, CA, USA). The area under the plasma concentration vs. time curve (AUC) was determined using the log-linear trapezoidal rule with extrapolation to infinitum and 13 normalized against the dose. The CL value is the volume of plasma completely cleared of a specific compound per unit time by the organism; it was calculated by dividing the dose by AUC. The maximum plasma concentration (C max ) was calculated from the plasma concentration-time curve and normalized against the dose. Oral bioavailability (F) was determined by ratio of the dose-normalized AUC following oral and i.v. administration. V ss is the volume of fluid that would be required to contain the amount of drug in the body if it were uniformly distributed at a concentration equal to that in the plasma. The t 1/2 value refers to the time taken for plasma concentration to fall by 50 %, and it was determined using the following formula: t 1/2 =ln (2)·V ss /CL.
Statistical analysis
The presence of differences in tissue/plasma ratios and pharmacokinetic parameters was measured by the Mann Whitney test for double comparisons using Social Package of Statistical Sciences (SPSS). Student's t test was used for measuring differences in efficacy and tumor dissemination inhibition studies.
A value of p < 0.05 was considered to be statistically significant for all statistical tests.
Results and discussion
Particle size, size distribution and zeta potential
The peroral route is the most preferred route of administration, but this path is limited for many substances as they present poor oral bioavailability due to 14 biopharmaceutical (low solubility, low permeability, and/or instability in gastrointestinal environment) and pharmacokinetic (extensive first pass metabolism and/or rapid clearance) drawbacks in their delivery approach.
Therefore, the development of delivery systems that would be able to overcome these drawbacks is essential to ensure the effectiveness of such molecules.
Edelfosine-loaded LN were produced by a solvent-free hot homogenization method followed by high shear homogenization and ultrasonication, and freezedried. The physical-chemical characteristics of the developed nanoparticles are compiled in Table I . Zeta (ζ) potential can make a prediction about the stability of colloid dispersions. A high ζ potential (>|30| mV) can provide an electric repulsion to avoid the aggregation of particles, as they are considered strongly ionic [21, 28] . In our case, the ζ-potential values measured in double-distilled water were another effect which would increase the stability of colloidal dispersions [29] .
Loading capacity
It is well known that the crystalline state in the LN structure leads to faster drug expulsion. However, lattice defects of the lipid structure offer space to accommodate the drugs [30] . As a result, the structure of less ordered arrangement in the nanoparticles should be beneficial to the drug loading capacity, as in the case of the particles developed in this work.
The entrapment efficiency of edelfosine in the LN prepared by the warm microemulsion followed by high shear homogenization and ultrasonication was similar for nanoparticles prepared with both types of lipids (Table I) .
Nanoparticles formulated using Compritol ® encapsulated 84.68 ± 7.18 % of edelfosine (equivalent to 17.57 ± 1.97 µg edelfosine/mg formulation), while Precirol ® LN encapsulated 82.62 ± 5.73 % of the drug (13.95 ± 0.79 µg edelfosine/mg formulation). This high encapsulation efficiency is likely to be due to the partially amorphous state of the lipids in the formulation, which allows more edelfosine to be incorporated among lipid chains [7] .
Hemolytic experiments
Edelfosine presents hemolytic toxicity due to its amphipathic structure [31] . Therefore, a hemolytic assay was performed to assess whether LN reduced the hemolytic effect of edelfosine. Results clearly showed that LN protected red blood cells from hemolysis caused by edelfosine, because while the free drug was 100 % hemolytic at 10 µg/mL, both drug-loaded and unloaded [3] . As a result, LN showed a significant decrease in hemolytic toxicity of edelfosine. Whichever the type of nanoparticle employed, the highest accumulations of the drug were achieved in kidney, intestine and liver, followed by spleen, stomach and lung, with no statistical differences between the ratios.
Pharmacokinetic characterization and biodistribution after intravenous administration
Pharmacokinetic characterization and biodistribution after oral administration
Pharmacokinetic studies were performed after a single oral administration of 50 mg/kg of edelfosine-loaded in LN. This oral dose was well tolerated by the mice and no hemolytic side effects or body weight loss was observed (data not shown). Figure 3 shows the concentration of edelfosine in mouse plasma plotted against time after a single oral administration of edelfosine-loaded LN to BALB/c mice. 
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The endpoint of the experiment was the day after the concentration of edelfosine in plasma reached 0.5 µg/mL. It can be observed that unlike edelfosine solution, drug-loaded LN enhanced the absorption of the drug maintaining detectable concentrations for over seven days. As a result, the maintenance times in plasma achieved with the developed LN were much longer than those observed by different studies recently published with the same Compritol ® lipid, which did not last longer than 24 h [27, 32] .
All dose-normalized pharmacokinetic parameters obtained after the administration of edelfosine in LN are summarized in Table III . The maximum concentration (C max /dose) after the administration was 0.007 ± 0.001 µg/mL/µg and 0.012 ± 0.006 µg/mL/µg for Compritol ® and Precirol ® LN, respectively, after 15 h, which is the time at which peak concentration is reached (T max ). In previous studies, we hypothesized that the interaction of edelfosine with P-glycoprotein (P-gp) could be the explanation for the lack of gastrointestinal absorption of the drug [2] . However, the Tween ® 80 present in the composition of the LN shows an inhibition effect of P-gp [33, 34] . Therefore, both types of edelfosine-loaded LN crossed the gastrointestinal barrier and prolonged the release of the drug for over one week. Different authors had also observed this effect, after they administered different drugs via the oral route Owing to the expected slow release of edelfosine from the LN, it was decided to test a higher dose (50 mg/kg, a dose at which edelfosine still presents linear pharmacokinetics, data not shown) than that used for previous studies, to determine the pharmacokinetic and biodistribution profile of edelfosine-loaded in LN. As a result, the encapsulation of edelfosine in LN provided an increase in relative oral bioavailability of 1500 %. It is interesting to note that even if multiple administration of free edelfosine was able to increase the bioavailability of the drug up to 64 %, it presents the drawback of causing gastrointestinal irritation [4, 5] . On the other hand, the oral administration of LN greatly 
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The tissue distribution expressed as edelfosine concentration after the administration of a drug dose of 50 mg/kg to mice is shown in Figure 4 . 
In vivo efficacy of edelfosine-loaded LN
Previous studies have provided evidence for the uptake and transport of LN in the lymph and, to a lesser extent, in the blood [43] . Therefore, due to the ability of the developed LN to be absorbed by the lymphatic system, we hypothesized that LN could be able to treat lymphatic diseases, and in particular, lymphomas.
It is known that the therapy for lymphatic neoplasms is comprised of different drugs that always involve several hematological side effects [20] .
Edelfosine lacks those negative secondary effects because it causes no mielotoxicity [1] . Besides, this drug has already been effective in in vitro experiments against JVM-2 mantle-cell lymphoma cell line [44] . However, we have to bear in mind that edelfosine presents low bioavailability [2] and may cause hemolysis at high concentrations [31] . In this study, LN with a suitable size for oral administration have been developed; these LN increase the bioavailability and avoid hemolysis, so an in vivo experiment was designed with MCL-bearing mice to evaluate the efficacy of the drug-loaded LN ( Figure 5 ). It is remarkable that a daily administration of 30 mg/kg edelfosine was mandatory to diminish the tumor burden of MCL bearing mice as much as Compritol ® and Precirol ® LN did after the treatment every four days ( Figure 5A ). Besides, the treatment of mice with Compritol ® LN every four days reduced the tumor weight more efficiently than the daily administration of edelfosine solution ( Figure 5B ). significantly, compared to the control. These data show that edelfosine-loaded LN present a potential anti-lymphoma effect and could be tested as treatment against lymphomas. Besides, these drug-loaded nanoparticulate systems do not present the side effects that other antineoplastic drugs do [16, 45] .
Due to the confirmation that edelfosine-loaded LN circulate through lymph nodes, by the present study as well as by other researchers [32] , we also wanted to assess the ability of these delivery systems to inhibit extranodal dissemination of MCL cells. For that reason, axilary, inguinal and mesenteric lymph nodes were also extracted from MCL-bearing mice treated with either 29 free or vectorized edelfosine and macroscopically analyzed. As can be seen in Figure 6 , all the lymphatic metastases were not completely removed after the treatment with a daily oral administration of edelfosine solution to mice, and a certain degree of extranodal dissemination could still be observed. against breast cancer and its metastases after a local injection; however, they did not achieve complete eradication of the extranodal dissemination [46] . This complete inhibition of the metastases can be mainly attributed to the lymphatic absorption and accumulation of LN in the thoracic duct, which acts as a 30 reservoir, and from which LN are continuously released throughout lymph nodes. This outcome is of great interest in the treatment of different types of lymphomas, especially via the oral route, as no orally administered treatments have been described yet [47, 48] ; therefore, our results concerning edelfosineloaded LN as being effective against both MCL and its lymph node metastases shows a strong potential to benefit the improvement of clinical efficiency.
4.
Conclusions
The data presented above give evidence that it was possible to produce LN endowed with high encapsulation efficiency and with a well-determined size 
Future perspective
The development of LN that target the extranodal dissemination of hematological disorders opens a promising path in the treatment of these diseases. New therapies using drug loaded LN will be designed to focus and increase the therapeutic efficacy of drugs against diseases, while decreasing their secondary effects. Moreover, the oral administration of these delivery systems will increase the patients' compliance.
Executive Summary
Edelfosine loaded lipid nanoparticles increased oral bioavailability in 1500%.
Lipid nanoparticles were absorbed through the lymphatic system.
Drug loaded lipid nanoparticles inhibited 100% of extranodal dissemination in mantle cell lymphoma bearing mice.
